Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Glaucoma News

12/6/2024
BreakingDiagnosticGlaucomaPerimetry
Konan Medical Launches ObjectiveField Perimeter in US
Konan Medical Launches ObjectiveField Perimeter in US

Konan Medical has launched its ObjectiveField visual field analyzer in the US. The ObjectiveField is an objective perimeter designed to detect visual field abnormalities using pupillary responses. ...

12/6/2024
AIBreakingDealsDiagnosticFundusGlaucomaRetina
Avant, Ainnova Advancing Low-Cost Retinal Camera with AI Screening Software
Avant, Ainnova Advancing Low-Cost Retinal Camera with AI Screening Software

Nevada-based Avant Technologies and Ainnova Tech, of Houston, Texas, announced Nov. 20 that the two companies would advance Ainnova’s proprietary low-cost retinal camera packaged with the Vision AI...

11/27/2024
BreakingGlaucomaLaserMIGSRegulationSurgical
MACs Finalize Coverage for Standalone and Combo MIGS Procedures
MACs Finalize Coverage for Standalone and Combo MIGS Procedures

Five Medicare administrative contractors have issued their final coverage policies for minimally invasive glaucoma surgery, or MIGS, along with more technical billing and coding documents. The poli...

11/27/2024
BreakingClinical TrialGlaucomaPharma
Nicox Chooses Higher Dose of NCX 470 to Advance in Phase III Glaucoma Trials
Nicox Chooses Higher Dose of NCX 470 to Advance in Phase III Glaucoma Trials

France’s Nicox announced Nov. 19 that it had chosen the higher dose of NCX 470 ophthalmic solution to advance in the Phase III Mont Blanc trial in glaucoma. The company said both doses tested—0.065...

11/22/2024
BreakingCataractGlaucomaLaserRegulationRetinaSurgical
CMS Cuts Ophthalmologists’ Procedure Fees, While Raising ASC, HOPD Facility Fees
CMS Cuts Ophthalmologists’ Procedure Fees, While Raising ASC, HOPD Facility Fees

The Centers for Medicare and Medicaid Services (CMS) published on Nov. 1 the final schedule of Medicare reimbursement fees for physicians in 2025. It also released its facility fee payments for ASC...

11/22/2024
BreakingCataractGlaucomaPharmaRegulation
Harrow’s ImprimisRx Unit Gets $34.9 Million Trademark Infringement Verdict
Harrow’s ImprimisRx Unit Gets $34.9 Million Trademark Infringement Verdict

Harrow’s ImprimisRx subsidiary received a $34.9 million verdict on Nov. 20, 2024, in a trademark infringement lawsuit against OSRX Pharmaceuticals, of Missoula, Montana. OSRX is an affiliate of Ocu...

11/15/2024
BreakingCataractChinaDry EyeGlaucomaIOLLaserRevenueSurgical
Q3-2024 Ophthalmic Revenue Roundup for Alcon, Hoya, RxSight, Sight Sciences, and Iridex
Q3-2024 Ophthalmic Revenue Roundup for Alcon, Hoya, RxSight, Sight Sciences, and Iridex

Alcon reported Nov. 12 that its Q3-2024 net sales totaled $2.4 billion, a 6 percent increase over $2.3 billion in Q3-2023. Surgical net sales for implantables, consumables, and equipment/other were...

11/14/2024
AIDealsDiagnosticFundingGene TherapyGlaucomaNewsletterRetinaSurgical
EyePoint Leads Latest Ophthalmic Fundraising with $161 Million Public Offering
EyePoint Leads Latest Ophthalmic Fundraising with $161 Million Public Offering

EyePoint Pharmaceuticals led recent ophthalmic fundraising efforts with a $161 million upsized underwritten public offering. Proceeds in part will fund clinical development of Duravyu. Financing an...

11/14/2024
AAOGlaucomaMeetingNewsletterRetina
Weighing the Ophthalmic Impact of Boom in GLP-1 Receptor Agonist Treatment
Weighing the Ophthalmic Impact of Boom in GLP-1 Receptor Agonist Treatment

Recent studies indicate that up to 6 percent of the US population is currently taking a GLP-1 receptor agonist, a class of drugs prescribed to help manage blood glucose levels for diabetes and weig...

11/14/2024
AAODeviceEyeceleratorGlaucomaMeetingNewsletterSurgical
AAO and Eyecelerator Sessions Showcase Latest in Glaucoma Lasers and Surgical Devices
AAO and Eyecelerator Sessions Showcase  Latest in Glaucoma Lasers and Surgical Devices

New glaucoma lasers and surgical devices were shown at various venues during the 2024 AAO meeting, including Glaucoma Subspecialty Day and the Eyecelerator meeting. There was also an important upda...

11/8/2024
BreakingCataractEuropeGlaucomaIndiaIndustryMeetingNewsletterRefractiveRetina
2025-2026 Ophthalmic Meetings Calendar
2025-2026 Ophthalmic Meetings Calendar

Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.

11/14/2024
AllergyCataractClinical TrialCornealGlaucomaNewsletterPresbyopiaRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, November 2024
Clinical Trial Updates for Ophthalmic Candidates, November 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

11/14/2024
AIDiagnosticEmergingGlaucomaNewsletterOcular CancerRegulationRetinaTelehealth
Emerging Companies Pursuing Ophthalmic Indications, November 2024
Emerging Companies Pursuing Ophthalmic Indications, November 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

11/14/2024
CataractClinical TrialDealsDiagnosticDry EyeFundingGene TherapyGlaucomaIndustryInstrumentsMicroscopesNewsletterOCTPresbyopiaRegulationRetinaStudySurgical
November 2024 Ophthalmic News Briefs
November 2024 Ophthalmic News Briefs

Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...

11/8/2024
BreakingCataractCornealDry EyeGlaucomaLaserPharmaPresbyopiaRefractiveRetinaRevenueSurgical
Q3-2024 Ophthalmic Revenue Roundup for AbbVie, Apellis, Glaukos, STAAR, and Lensar
Q3-2024 Ophthalmic Revenue Roundup for AbbVie, Apellis, Glaukos, STAAR, and Lensar

AbbVie, of North Chicago, Illinois, reported Oct. 30 that its Q3-2024 eye care net revenue was $525 million, a 13.5 percent decline (-11.2 percent cc) from $605 million in Q3-2023. Restasis revenue...

10/18/2024
BreakingGlaucomaPharma
Spinogenix Unveils Glaucoma Program to Evaluate Once-Daily Neuroprotective Pill
Spinogenix Unveils Glaucoma Program to Evaluate Once-Daily Neuroprotective Pill

Los Angeles-based Spinogenix reported Oct. 16 that it was launching a program to evaluate SPG302 as a potential neuroprotective therapeutic for glaucoma. Spinogenix describes SPG302 as a once-a-day...

10/18/2024
BreakingDealsGlaucomaPharma
Nicox and Soleus Sign $16.5 Million Deal for Vyzulta Royalties, Equity Financing
Nicox and Soleus Sign $16.5 Million Deal for Vyzulta Royalties, Equity Financing

France’s Nicox announced Oct. 14 a deal with Soleus Capital under which Soleus will acquire Nicox’ royalties from the glaucoma treatment Vyzulta for $15 million, while providing $1.5 million in equ...

10/15/2024
EuropeGlaucomaNewsletterPharmaRegulation
AbbVie Withdraws EU Marketing Application for Durysta Implant for Glaucoma
AbbVie Withdraws EU Marketing Application for Durysta Implant for Glaucoma

Europe’s Committee for Medicinal Products for Human Use (CHMP) announced Sept. 19 that AbbVie had withdrawn its marketing authorization application for the sustained-release glaucoma implant Duryst...

10/15/2024
CornealDiagnosticGlaucomaLaserNewsletterRegulation
Select US FDA Approvals and Clearances in September 2024
Select US FDA Approvals and Clearances in September 2024

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in September 2024, according to the agency’s database. Zeiss gained clearance for its combination Y...

10/15/2024
Clinical TrialESCRSEuropeGlaucomaLaserMeetingNewsletter
ViaLase Releases Latest Glaucoma Laser Data at ESCRS Congress
ViaLase Releases Latest Glaucoma Laser Data at ESCRS Congress

Rick Lewis, MD, chief medical officer at ViaLase, provided an update at the 2024 ESCRS congress on the ViaLuxe glaucoma laser, including the system’s most recent clinical trial results. The ViaLuxe...

10/15/2024
Clinical TrialCornealDry EyeGene TherapyGlaucomaIOLNewsletterOcular CancerRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, October 2024
Clinical Trial Updates for Ophthalmic Candidates, October 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

10/15/2024
ChinaClinical TrialDealsDiagnosticDry EyeEuropeGene TherapyGlaucomaIndiaIndustryLaserNewsletterPerimetryRegulationRetinaSurgical
October 2024 Ophthalmic News Briefs
October 2024 Ophthalmic News Briefs

Oculus has announced the addition of frequency doubling perimetry (FDP) to its Easyfield VR visual field diagnostic headset. The German ophthalmic diagnostic company, with US headquarters in Arling...

10/11/2024
BreakingDiagnosticGlaucoma
iCare Launches ST500 Slit Lamp Mounted Rebound Tonometer
iCare Launches ST500 Slit Lamp Mounted Rebound Tonometer

Finland’s iCare, a subsidiary of Revenio Group, has launched its iCare ST500 rebound tonometer that can be attached to a slit lamp. The device gained US FDA 510(k) clearance on Sept. 27. The compan...

10/11/2024
BreakingGlaucomaIndustryLaserRetina
Iridex Appoints Patrick Mercer as Chief Executive Officer
Iridex Appoints Patrick Mercer as Chief Executive Officer

Iridex reported Oct. 3 that it had appointed Patrick Mercer as chief executive officer, to go along with his role as president, effective Oct. 1. Mercer had also served as the company’s chief opera...

9/27/2024
BreakingEuropeGlaucomaPharmaRegulation
AbbVie Withdraws EU Marketing Application for Durysta
AbbVie Withdraws EU Marketing Application for Durysta

Europe’s Committee for Medicinal Products for Human Use (CHMP) announced Sept. 19 that AbbVie had withdrawn its marketing authorization application for the sustained-release glaucoma implant Duryst...

9/27/2024
BreakingDealsGlaucomaRetina
Nicox, Glaukos Sign Research and Option Agreement for Glaucoma Candidate
Nicox, Glaukos Sign Research and Option Agreement for Glaucoma Candidate

France’s Nicox announced Sept. 23 that it had signed an exclusive research and license option agreement with Glaukos for NCX 1728, Nicox’s novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5...

9/20/2024
BreakingDealsGlaucomaPharma
Ripple, AbbVie to Collaborate on Fully Biodegradable Bimatoprost Implant for Glaucoma
Ripple, AbbVie to Collaborate on Fully Biodegradable Bimatoprost Implant for Glaucoma

Ripple Therapeutics, of Toronto, Canada, announced Sept. 17 that it had signed a collaboration agreement with AbbVie to develop RTC-620, a fully biodegradable sustained-release intracameral bimatop...

9/19/2024
CataractGlaucomaNewsletterRefractiveRetina
Ophthalmologists Report 0.5 Percent Increase in Q2-2024 Procedure Volume
Ophthalmologists Report 0.5 Percent Increase in Q2-2024 Procedure Volume

US ophthalmologists reported that ophthalmic procedures increased 0.5 percent in Q2-2024 compared with the same quarter in 2023, according to Market Scope’s latest survey. Year-over-year performanc...

9/19/2024
DeviceDiagnosticGlaucomaNewsletter
Injectsense Reports First Human Implantation of Ultraminiature IOP Sensor
Injectsense Reports First Human Implantation of Ultraminiature IOP Sensor

Injectsense, of Emeryville, California, announced Aug. 27 that it had implanted its first ultraminiature wireless sensor for measuring intraocular pressure (IOP). Glaucoma specialist Juan Mura, MD,...

9/19/2024
CataractDealsGlaucomaNewsletterPharma
Visiox to Merge with Ocuvex to Advance Two Ophthalmic Drug Candidates
Visiox to Merge with Ocuvex to Advance Two Ophthalmic Drug Candidates

Visiox Pharmaceuticals announced Aug. 19 that it had agreed to merge with Ocuvex Therapeutics, a privately held company in New Hyde Park, New York. A Visiox news release said Ocuvex has a pipeline ...

9/19/2024
AmblyopiaClinical TrialDiagnosticFundusGene TherapyGlaucomaIndustryNewsletterRegulationRetinaSurgical
September 2024 Ophthalmic News Briefs
September 2024 Ophthalmic News Briefs

Bausch + Lomb is working with Goldman Sachs to explore a sale of the company, the Financial Times reported Sept. 14, with private equity the most likely buyer. The move is being evaluated as a way ...

9/13/2024
BreakingDiagnosticGlaucomaPerimetry
Oculus Debuts Frequency Doubling Perimetry with Easyfield VR
Oculus Debuts Frequency Doubling Perimetry with Easyfield VR

Oculus has announced the addition of frequency doubling perimetry (FDP) to its Easyfield VR visual field diagnostic headset, along with standard automated perimetry. The German ophthalmic diagnosti...

9/13/2024
BreakingGlaucomaIndustryMIGSSurgical
iStar Medical Appoints Richard Beckman, MD, as Chief Medical Officer
iStar Medical Appoints Richard Beckman, MD, as Chief Medical Officer

Belgium’s iStar Medical announced Sept. 4 that it had appointed Richard Beckman, MD, as chief medical officer and member of the company’s board. Beckman most recently served as CMO of Adverum Biote...

9/6/2024
BreakingClinical TrialDiagnosticGlaucoma
Injectsense Completes First Human Implantation of its Ultraminiaturized IOP Sensor
Injectsense Completes First Human Implantation of its Ultraminiaturized IOP Sensor

Injectsense, of Emeryville, California, announced Aug. 27 that it had implanted its first ultraminiature wireless sensor for measuring intraocular pressure (IOP). Glaucoma specialist Juan Mura, MD,...

8/30/2024
AIBreakingDealsDiagnosticEuropeGlaucomaRetina
Revenio’s iCare Subsidiary Acquires AI Screening Company Thirona Retina
Revenio’s iCare Subsidiary Acquires AI Screening Company Thirona Retina

Finland’s Revenio Group announced Aug. 20 that its iCare subsidiary had assumed ownership of the Dutch artificial intelligence (AI) software company Thirona Retina. iCare had made a minority invest...

8/23/2024
BreakingDealsGlaucomaPharma
Visiox to Merge with Ocuvex to Advance Candidates for Glaucoma, Postsurgical Pain and Inflammation
Visiox to Merge with Ocuvex to Advance Candidates for Glaucoma, Postsurgical Pain and Inflammation

Visiox Pharmaceuticals announced Aug. 19 that it had agreed to merge with Ocuvex Therapeutics, a privately held company in New Hyde Park, New York. A Visiox news release said Ocuvex has a pipeline ...

8/21/2024
CataractEnvironmentGlaucomaNewsletterSingle-UseSurgical
Steady Growth Expected in Single-Use Surgical Products, Even With Push to Cut OR Waste
Steady Growth Expected in Single-Use Surgical Products, Even With Push to Cut OR Waste

Environmental sustainability programs have grown in scope over the last five years, with major ophthalmic surgery associations joining forces to propose specific actions to reduce the carbon footpr...

8/21/2024
EuropeGlaucomaLaserNewsletterRegulationSurgical
ViaLase Gains CE Marking for Femtosecond Laser for Glaucoma Treatment
ViaLase Gains CE Marking for Femtosecond Laser for Glaucoma Treatment

ViaLase announced July 30 that the European Union had granted CE marking for its ViaLase Laser for the treatment of adults with primary open-angle glaucoma. The system uses an OCT-guided femtosecon...

8/21/2024
Clinical TrialDry EyeGene TherapyGlaucomaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, August 2024
Clinical Trial Updates for Ophthalmic Candidates, August 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

8/21/2024
Dry EyeGlaucomaNewsletter
USC Alums Gift Eye Care Practice to Roski Eye Institute
USC Alums Gift Eye Care Practice to Roski Eye Institute

Richard Weise, MD, and his wife, Cathy, have gifted their ophthalmic practice, the Glendale Eye Medical Group, of Glendale, California, to the USC Roski Eye Institute, the university announced July...

8/16/2024
BiosimilarsBreakingCataractDiagnosticDry EyeGlaucomaLaserOcular CancerRefractiveRetinaRevenueSurgical
Q2-2024 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec, Amgen, STAAR, Astellas, Immunocore, Tarsus, Biogen, Lensar, and Iridex
Q2-2024 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec,  Amgen, STAAR, Astellas, Immunocore, Tarsus, Biogen, Lensar, and Iridex

AbbVie, of North Chicago, Illinois, reported July 25 that Q2-2024 net revenue for its eye care products totaled $533 million, a 13.3 percent decline (-10.9 percent cc) from $617 million in Q2-2023....

8/9/2024
BreakingCataractDry EyeGlaucomaIOLRetinaRevenueSurgical
Q2-2024 Ophthalmic Revenue Roundup for Hoya, Harrow, RxSight, Sight Sciences, Ocular Therapeutix, and EyePoint
Q2-2024 Ophthalmic Revenue Roundup for Hoya, Harrow, RxSight, Sight Sciences, Ocular Therapeutix, and EyePoint

Japan-based Hoya Corporation announced Aug. 1 that its medical care segment (IOLs, endoscopes, artificial bone) had revenue for the quarter ending June 30, 2024—the first quarter of its fiscal year...

8/9/2024
BreakingDry EyeGlaucoma
USC Alums Gift Eye Care Practice to Roski Eye Institute
USC Alums Gift Eye Care Practice to Roski Eye Institute

Richard Weise, MD, and his wife, Cathy, have gifted their ophthalmic practice, the Glendale Eye Medical Group, of Glendale, California, to the USC Roski Eye Institute, the university announced July...

8/2/2024
BreakingEuropeGlaucomaLaserRegulationSurgical
ViaLase Gains CE Marking for Femtosecond Laser for Glaucoma Treatment
ViaLase Gains CE Marking for Femtosecond Laser for Glaucoma Treatment

ViaLase announced July 30 that the European Union had granted CE marking for its ViaLase Laser for the treatment of adults with primary open-angle glaucoma. The system uses an OCT-guided femtosecon...

8/2/2024
BreakingCornealDiagnosticDry EyeGlaucomaIOLLaserRetinaRevenueSurgical
Q2-2024 Ophthalmic Revenue Roundup for Regeneron, Roche, Bausch + Lomb, Novartis, and Four Others
Q2-2024 Ophthalmic Revenue Roundup for Regeneron, Roche, Bausch + Lomb, Novartis, and Four Others

Regeneron, of Tarrytown, New York, reported Aug. 1 that its Q2-2024 US revenue for Eylea was $1.53 billion, a 2 percent increase from $1.5 billion in Q2-2023. Eylea HD accounted for $304 million of...

7/26/2024
BreakingGlaucomaIndustrySurgical
Cancer Company TME Pharma Plans to Spin Off NOX-E36 for Eye Disease
Cancer Company TME Pharma Plans to Spin Off NOX-E36 for Eye Disease

Germany’s TME Pharma, a clinical-stage cancer company, announced July 22 that it planned to spin off its asset NOX-E36 to advance it for eye disease. NOX-E36 is an L-stereoisomer RNA aptamer inhibi...

7/23/2024
DeviceGlaucomaNewsletterSurgical
Multitude of Novel Glaucoma Surgery Devices to Drive Procedure Growth
Multitude of Novel Glaucoma Surgery Devices to Drive Procedure Growth

The goal of a growing number of companies entering the already crowded glaucoma device market is to provide surgical treatment options with greater safety and effectiveness. Thirty-six products are...

7/23/2024
DeviceGlaucomaNewsletterRegulation
IOP-Lowering Goggles Developed by John Berdahl, MD, Gain De Novo Certification for Marketing
IOP-Lowering Goggles Developed by John Berdahl, MD, Gain  De Novo Certification for Marketing

Balance Ophthalmics has gained US FDA de novo classification for its FSYX Ocular Pressure Adjusting Pump (FSYX OPAP) system, a goggles and pump system designed to lower intraocular pressure (IOP) i...

7/23/2024
CataractGlaucomaNewsletterRegulation
Select US FDA Approvals and Clearances in June 2024
Select US FDA Approvals and Clearances in June 2024

The US FDA granted four clearances through the ophthalmic device division using the 510(k) pathway in June 2024, according to the agency’s database. Alcon gained clearance for its much-anticipated ...

7/23/2024
ChinaEmergingGene TherapyGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, July 2024
Emerging Companies Pursuing Ophthalmic Indications, July 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

7/23/2024
BiosimilarsClinical TrialCornealDealsDry EyeEuropeGene TherapyGlaucomaIndiaIndustryMyopiaNewsletterRegulationRetina
July 2024 Ophthalmic News Briefs
July 2024 Ophthalmic News Briefs

Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...

7/5/2024
BreakingDeviceGlaucomaRegulation
IOP-Lowering Goggles Developed by John Berdahl, MD, Gain De Novo Nod for Marketing
IOP-Lowering Goggles Developed by John Berdahl, MD, Gain De Novo Nod for Marketing

Balance Ophthalmics has gained US FDA de novo classification for its FSYX Ocular Pressure Adjusting Pump (FSYX OPAP) system, a goggles and pump system designed to lower intraocular pressure (IOP) i...

6/24/2024
GlaucomaIOLNewsletterRefractiveRetina
Ophthalmologists Report 6 Percent Decline in Q1-2024 Procedure Volume
Ophthalmologists Report 6 Percent Decline in Q1-2024 Procedure Volume

US ophthalmologists reported that ophthalmic procedures decreased 6.0 percent in Q1-2024 compared with the same quarter in 2023, according to Market Scope’s latest survey. Year-over-year performanc...

6/24/2024
Clinical TrialGlaucomaNewsletter
Skye Drops Glaucoma Program After Phase IIa Failure, Shifts Focus to Obesity
Skye Drops Glaucoma Program After Phase IIa Failure, Shifts Focus to Obesity

Skye Bioscience reported June 10 that it was discontinuing its ophthalmology program after its synthetic cannabinoid derivative SBI-100, a glaucoma drop candidate, failed to meet its Phase IIa prim...

6/24/2024
DiagnosticFundusGlaucomaIOLNewsletterOCTRegulationSurgical
Select US FDA Approvals and Clearances in May 2024
Select US FDA Approvals and Clearances in May 2024

The US FDA granted six clearances through the ophthalmic device division using the 510(k) pathway in May 2024, according to the agency’s database. Reichert gained market clearance for its new hand-...

6/24/2024
CataractGlaucomaNewsletterRegulationSurgical
Surgeons, Societies Respond to MACs’ New Proposed MIGS Limits
Surgeons, Societies Respond to MACs’ New Proposed MIGS Limits

Surgeons and ophthalmic societies worked together at open meetings in June to address five Medicare administrative contractors’ latest proposal to limit coverage of minimally invasive glaucoma surg...

6/24/2024
DealsDiagnosticFundingGene TherapyGlaucomaNewsletterPharmaRetinaTelehealth
Opthea Leads Latest Fundraising with $113.2M Placement, Entitlement Offer
Opthea Leads Latest Fundraising with $113.2M Placement, Entitlement Offer

Opthea led recent ophthalmic fundraising efforts with a $113.2 million placement and entitlement offer, as it continues to advance its wet AMD candidate. Financing announced in the past four weeks ...

6/24/2024
CataractClinical TrialData SecurityDealsDiagnosticDry EyeGene TherapyGlaucomaIOLIndustryMyopiaNewsletterRefractiveRegulationRetinaSurgical
June 2024 Ophthalmic News Briefs
June 2024 Ophthalmic News Briefs

Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas OCT system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlined workflow and advanced analyt...

6/14/2024
BreakingClinical TrialGlaucomaIndustry
Skye Drops Glaucoma Program After Phase IIa Failure, Shifts Focus to Obesity
Skye Drops Glaucoma Program After Phase IIa Failure, Shifts Focus to Obesity

Skye Bioscience reported June 10 that it was discontinuing its ophthalmology program after its synthetic cannabinoid derivative SBI-100, a glaucoma drop candidate, failed to meet its Phase IIa prim...

6/14/2024
BreakingDiagnosticGlaucomaOCTRetina
Nidek Launches RS-1 Glauvas OCT System
Nidek Launches RS-1 Glauvas OCT System

Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas optical coherence tomography (OCT) system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlin...

6/7/2024
BreakingGlaucomaRegulationSurgical
MACs Propose New Limits on MIGS Procedures
MACs Propose New Limits on MIGS Procedures

Five Medicare administrative contractors have proposed new limits to their coverage of minimally invasive glaucoma surgery (MIGS). The move comes a year after the same MACs roiled the glaucoma subs...

5/24/2024
BiosimilarsBreakingDry EyeGlaucomaLaserRetinaRevenue
Q1-2024 Ophthalmic Revenue Roundup for AbbVie, Iridex, and Biogen
Q1-2024 Ophthalmic Revenue Roundup for AbbVie, Iridex, and Biogen

AbbVie, of North Chicago, Illinois, reported April 26 that its Q1-2024 eye care net revenue totaled $538 million, an 11.7 percent decline (-10.4 percent cc) from $608 million in Q1-2023. Restasis r...

5/24/2024
BreakingGlaucomaRegulationSurgical
New World Medical Gains US 510(k) Clearance for KDB Glide
New World Medical Gains US 510(k) Clearance for KDB Glide

New World Medical reported May 22 that its Kahook Dual Blade Glide (KDB Glide) had gained US FDA 510(k) clearance. The KDB Glide was previously classified as a Class 1, 510(k)-exempt device. With t...

5/24/2024
BreakingDiagnosticGlaucoma
Reichert Launches Tono-Vera Hand-held Tonometer in US
Reichert Launches Tono-Vera Hand-held Tonometer in US

Reichert announced May 6 that its Tono-Vera hand-held tonometer is now available in the US. Tono-Vera provides quick, automated, and reliable intraocular pressure measurements with rebound tonomete...

5/22/2024
AcquisitionsDealsGlaucomaLaserNewsletter
Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335M
Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335M

Alcon is acquiring Israel’s Belkin Vision, maker of the Eagle laser for glaucoma, for up to $335 million, according to reports. The value of the transaction was first estimated in a story dated May...

5/22/2024
AICataractDiagnosticFundingGene TherapyGlaucomaIOLNewsletterRetina
RxSight Leads Latest Ophthalmic Fundraising with $115 Million Public Offering
RxSight Leads Latest Ophthalmic Fundraising with $115 Million Public Offering

RxSight led recent ophthalmic fundraising efforts with a $115 million public offering to continue commercialization of its Light Adjustable Lens portfolio. Financing announced in the past four week...

5/22/2024
CornealDiagnosticDry EyeEmergingGene TherapyGlaucomaNewsletterOcular CancerRetinaSurgical
Emerging Companies Pursuing Ophthalmic Indications, May 2024
Emerging Companies Pursuing Ophthalmic Indications, May 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

5/22/2024
AIDealsDiagnosticGlaucomaMeetingNewsletterRetinaStudy
Artificial Intelligence Takes Leading Role at 2024 ARVO Meeting
Artificial Intelligence Takes Leading Role at 2024 ARVO Meeting

Artificial intelligence was a prominent topic at the 2024 ARVO meeting. Discussions ranged from using AI in published ophthalmic research to employing it in early detection and monitoring of eye di...

5/22/2024
CornealGlaucomaMeetingNewsletterOcular CancerRetinaStudy
2024 ARVO Awards Highlight New Focus on Inflammation
2024 ARVO Awards Highlight New Focus on Inflammation

The Weisenfeld and Cogan awards and lectures at the 2024 ARVO meeting put a spotlight on inflammation. Martine Jager, MD, PhD (Netherlands), received the Weisenfeld Award in recognition of her pion...

5/22/2024
CataractClinical TrialCornealGene TherapyGlaucomaNewsletterPharmaRefractiveRetina
Clinical Trial Updates for Ophthalmic Candidates, May 2024
Clinical Trial Updates for Ophthalmic Candidates, May 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

5/22/2024
GlaucomaNewsletterPatentSurgical
Sight Sciences Announces $34 Million Jury Verdict in Patent Infringement Case
Sight Sciences Announces $34 Million Jury Verdict in Patent Infringement Case

Sight Sciences, of Menlo Park, California, reported April 29 that it had received a $34 million jury trial verdict in its patent infringement case against Ivantis and acquirer Alcon. The suit, file...

5/22/2024
CataractChinaCornealDiagnosticDry EyeGlaucomaIndiaMicroscopesNewsletterPharmaRegulationRetina
May 2024 Ophthalmic News Briefs
May 2024 Ophthalmic News Briefs

Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...

5/10/2024
AcquisitionsBreakingDealsGlaucomaLaser
Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335 Million
Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335 Million

Alcon is acquiring Israel’s Belkin Vision, maker of the Eagle laser for glaucoma, for up to $335 million, according to reports. The value of the transaction was first estimated in a story dated May...

5/10/2024
BreakingCataractDry EyeGlaucomaRefractiveRetinaRevenueSurgical
Q1-2024 Ophthalmic Revenue Roundup for Apellis, STAAR, RxSight, Tarsus, Sight Sciences, and Three Others
Q1-2024 Ophthalmic Revenue Roundup for Apellis, STAAR, RxSight, Tarsus, Sight Sciences, and Three Others

Apellis Pharmaceuticals, of Waltham, Massachusetts, reported May 7 that its Q1-2024 US net product revenue for Syfovre was $137.5 million, compared with $18.4 million in Q1-2023. Syfovre gained US ...

5/10/2024
BreakingDiagnosticGlaucoma
First-in-Human Study for Injectsense Implantable IOP Monitor Approved by Chilean Clinic
First-in-Human Study for Injectsense Implantable IOP Monitor Approved by Chilean Clinic

Injectsense announced May 6 that the ethics committee at the Centro de la Vision Clinic in Santiago, Chile, has approved a 20-patient study of the company’s ultra-miniature wireless sensor, designe...

5/3/2024
BreakingCataractDry EyeGlaucomaLaserRevenueSurgical
Q1-2024 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, and Lumibird
Q1-2024 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, and Lumibird

Bausch + Lomb reported May 1 that its Q1-2024 revenue was $1.1 billion, an 18 percent increase (+20 percent cc) over $931 million in Q1-2023. Vision Care segment revenue in Q1-2024 was $635 million...

5/3/2024
BreakingGlaucomaPatentSurgical
Sight Sciences Announces $34 Million Jury Verdict in Patent Infringement Case
Sight Sciences Announces $34 Million Jury Verdict in Patent Infringement Case

Sight Sciences, of Menlo Park, California, reported April 29 that ithad received a $34 million jury trial verdict in its patent infringement case against Ivantis and acquirer Alcon. The suit, filed...

4/26/2024
BreakingGlaucomaPharmaRetinaRevenue
Q1-2024 Ophthalmic Revenue Roundup for Roche, Novartis, and Nicox
Q1-2024 Ophthalmic Revenue Roundup for Roche, Novartis, and Nicox

Swiss company Roche reported April 24 that Vabysmo sales in Q1-2024 were CHF 847 million ($926.5 million, calculated April 24, 2024), up from CHF 432 million (US $487 million) in Q1-2023. Vabysmo r...

4/26/2024
BreakingCataractGlaucomaOcular CancerRetinaStudy
Researchers in Georgia Establish Database of Proteins in Aqueous Humor to Advance Vision Research
Researchers in Georgia Establish Database of Proteins in Aqueous Humor to Advance Vision Research

The National Eye Institute (NEI) announced April 8 that researchers from the Medical College of Georgia at Augusta University had established a database of the proteins found in the eye’s aqueous h...

4/24/2024
GlaucomaNewsletterPharma
Second Shake-up May be Underway in the Glaucoma Pharmaceuticals Market
Second Shake-up May be Underway in the Glaucoma Pharmaceuticals Market

Allergan and Novartis replaced Merck and Pfizer at the top of the glaucoma pharmaceuticals market a decade ago. Now it could be their turn to pass the baton. Allergan, acquired by AbbVie in 2020 an...

4/24/2024
GlaucomaNewsletterRetina
iDose, Eylea HD, Izervay Get J-Codes for Billing Payers in the US
iDose, Eylea HD, Izervay Get J-Codes for Billing Payers in the US

The Centers for Medicare and Medicaid Services (CMS) has issued J-codes for Glaukos’ iDose, Regeneron’s Eylea HD, and Astellas Pharma’s Izervay. The code for iDose takes effect July 1, 2024, while ...

4/24/2024
AICataractCornealDiagnosticFundingGlaucomaIndiaLaserNewsletterPharmaRetina
Outlook Leads Latest Ophthalmic Fundraising with $164M in Private Placements
Outlook Leads Latest Ophthalmic Fundraising with $164M in Private Placements

Retinal drug developer Outlook Therapeutics led recent ophthalmic fundraising efforts with two private placements, for proceeds totaling $164 million. Financing announced in the past four weeks tot...

4/24/2024
GlaucomaNewsletterPharma
Study Attempts to Clarify Best Fit for Vyzulta
Study Attempts to Clarify Best Fit for Vyzulta

Constance Okeke, MD, is helping to clear the confusion that can come from having multiple choices. “There are so many medicines coming into glaucoma that it can be difficult for a clinician to know...

4/24/2024
GenericsGlaucomaNewsletterPharmaRegulation
Generic Drugmakers Sued by Large Employers in Price Fixing Scheme
Generic Drugmakers Sued by Large Employers in Price Fixing Scheme

Nine large employers—including American Airlines, Aramark, General Motors, Target, and Lowe’s—have filed a new lawsuit against leading makers of generic drugs, claiming the drugmakers have engaged ...

4/24/2024
Clinical TrialCornealGene TherapyGlaucomaLow VisionNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates , April 2024
Clinical Trial Updates for Ophthalmic Candidates , April 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

4/24/2024
Clinical TrialCornealData SecurityDealsDiagnosticDry EyeEnvironmentFundingGlaucomaIOLIndustryMicroscopesNewsletterRegulationRetina
April 2024 Ophthalmic News Briefs
April 2024 Ophthalmic News Briefs

Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for adults with neuromyelitis opt...

4/12/2024
BreakingGenericsGlaucomaPharmaRegulation
Leading Generic Drugmakers Sued by Large Employers in Price Fixing Scheme
Leading Generic Drugmakers Sued by Large Employers in Price Fixing Scheme

Nine large employers—including American Airlines, Aramark, General Motors, Target, and Lowe’s—have filed a new lawsuit against leading makers of generic drugs, claiming the drugmakers have engaged ...

4/12/2024
BreakingEmergingEuropeFundingGlaucomaSurgical
LEP Raises Funding to Advance Glaucoma Implant Targeting Inflammation, Fibrosis
LEP Raises Funding to Advance Glaucoma Implant Targeting Inflammation, Fibrosis

Ireland-based LEP Biomedical reported April 4 that it had closed a pre-seed funding round of €100 thousand to advance its HyaGuard platform. HyaGuard is a biodegradable, subconjunctival insert desi...

4/5/2024
BreakingGlaucomaRegulation
Glaukos’ iDose Gets J-Code for Medical Billing in the US
Glaukos’ iDose Gets J-Code for Medical Billing in the US

The Centers for Medicare and Medicaid Services (CMS) has issued a J-code for Glaukos’ iDose. The billing code takes effect July 1, 2024. iDose TR gained US FDA approval under the 505(b)(2) pathway ...

4/5/2024
BreakingGlaucomaIndustryPharma
Nicox Appoints Gavin Spencer, PhD, as Chief Executive Officer
Nicox Appoints Gavin Spencer, PhD, as Chief Executive Officer

France’s Nicox announced that it had appointed Gavin Spencer, PhD, as chief executive officer, effective Feb. 28. Spencer was most recently executive vice president, chief business officer, and hea...

3/29/2024
BreakingDry EyeGlaucomaLaserRevenue
2023 Ophthalmic Revenue Roundup for Iridex and NovaBay
2023 Ophthalmic Revenue Roundup for Iridex and NovaBay

Iridex, of Mountain View, California, reported March 26 that its 2023 revenue was $51.9 million, a 9 percent decrease from $57 million in 2022. Cyclo G6 product revenue was $13.4 million, a 9 perce...

3/21/2024
CataractGlaucomaIOLNewsletterRetina
Ophthalmologists Report 1.8 Percent Decline in Q4-2023 Procedure Volume
Ophthalmologists Report 1.8 Percent Decline in Q4-2023 Procedure Volume

----- Refractive: -12.1 IOL: 5.4 Glaucoma: 4.8 Retina: -4.4 ----- US ophthalmologists reported that ophthalmic procedures decreased 1.8 percent in Q4-2023 compared with the same quarter in 2022, ac...

3/21/2024
CornealGlaucomaNewsletterSurgical
CorNeat Vision Launches EverPatch Ophthalmic Graft Material in the US
CorNeat Vision Launches EverPatch Ophthalmic Graft Material in the US

Israel-based CorNeat Vision announced Feb. 27 that it had launched its EverPatch scleral reinforcement patch in the US. The device was cleared by the US FDA in June 2023. The graft is the first syn...

3/21/2024
CataractDiagnosticGlaucomaNewsletterRefractiveRegulationRetinaSurgical
Select US FDA Approvals and Clearances in February 2024
Select US FDA Approvals and Clearances in February 2024

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in February 2024, according to the agency’s database. CATS Tonometer received clearance for its ton...

3/21/2024
GlaucomaNewsletterPharmaSurgical
Celanese Announces Launch of Glaukos’ iDose TR Travoprost Implant
Celanese Announces Launch of Glaukos’ iDose TR Travoprost Implant

Celanese announced the commercial launch Feb. 29 of Glaukos’ iDose TR intracameral travoprost implant for glaucoma. Celanese, a specialty materials and chemical company based in Dallas, Texas, prod...

3/21/2024
Clinical TrialDry EyeGene TherapyGlaucomaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, March 2024
Clinical Trial Updates for Ophthalmic Candidates, March 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

3/21/2024
AllergyDiagnosticDry EyeEmergingGene TherapyGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, March 2024
Emerging Companies Pursuing Ophthalmic Indications, March 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

3/15/2024
BreakingCataractDry EyeGlaucomaRevenueSurgical
2023 Ophthalmic Revenue Roundup for Sight Sciences and Ocular Therapeutix
2023 Ophthalmic Revenue Roundup for Sight Sciences and Ocular Therapeutix

Sight Sciences reported March 7 that it generated 2023 total revenue of $81.1 million, an increase of 14 percent over $71.3 million in 2022. Surgical glaucoma revenue in 2023 was $74.3 million, a 1...

3/8/2024
BreakingGlaucomaPharmaSurgical
Celanese Announces Commercial Launch of Glaukos’ iDose TR Travoprost Implant
Celanese Announces Commercial Launch of Glaukos’ iDose TR Travoprost Implant

Celanese announced the commercial launch Feb. 29 of Glaukos’ iDose TR intracameral travoprost implant for glaucoma. Celanese, a global specialty materials and chemical company based in Dallas, Texa...

3/1/2024
BreakingCornealDry EyeGlaucomaIOLRefractiveRetinaRevenueSurgical
2023 Ophthalmic Revenue Roundup for Alcon, Bausch + Lomb, STAAR, Glaukos, Apellis, and Tarsus
2023 Ophthalmic Revenue Roundup for Alcon, Bausch + Lomb, STAAR, Glaukos, Apellis, and Tarsus

Alcon reported Feb. 27 that its full year 2023 net sales totaled $9.4 billion, an 8 percent increase (+10 percent cc) over $8.7 billion in 2022. Q4-2023 sales were $2.3 billion, an 8 percent increa...

3/1/2024
BreakingCornealGlaucomaSurgical
CorNeat Vision Launches EverPatch Ophthalmic Graft Material in the US
CorNeat Vision Launches EverPatch Ophthalmic Graft Material in the US

Israel-based CorNeat Vision announced Feb. 27 that it had launched itsEverPatch scleral reinforcement patch in the US. The device was cleared by the US FDA in June 2023. The graft is the first synt...

2/22/2024
GlaucomaMeetingNewsletter
Glaucoma 360 Showcases Innovation in Diagnosis, Management of Disease
Glaucoma 360 Showcases Innovation in Diagnosis, Management of Disease

Innovative diagnostics for glaucoma screening, staging, and management were a highlight of the Glaucoma 360 New Horizons Forum, with several physicians showcasing new approaches to visual field tes...

2/23/2024
BreakingEuropeGlaucomaMeetingSurgical
Sight Sciences Reports Launching of Omni Ergo-Series for Canaloplasty in Europe at ESCRS Winter Meeting
Sight Sciences Reports Launching of Omni Ergo-Series for Canaloplasty in Europe at ESCRS Winter Meeting

Sight Sciences announced Feb. 14 that it would launch the Ergo-Series of its Omni system for canaloplasty in Europe at the European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meetin...

2/22/2024
GlaucomaLaserNewsletterRefractiveRegulation
Select US FDA Approvals and Clearances in January 2024
Select US FDA Approvals and Clearances in January 2024

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in January 2024, according to the agency’s database. Meridian received clearance for three laser mo...

2/22/2024
DealsFundingGene TherapyGlaucomaNewsletterRetinaSurgical
4DMT Leads Latest Ophthalmic Fundraising with $300 Million Public Offering
4DMT Leads Latest Ophthalmic Fundraising with $300 Million Public Offering

4D Molecular Therapeutics led recent ophthalmic fundraising efforts with a $300 million upsized public offering to continue advancing its retinal gene therapy candidate. Financing announced in the ...

2/22/2024
GlaucomaMeetingNewsletterSurvey
Participation in the 2024 Glaucoma 360 Attendee Survey Hits All-Time High
Participation in the 2024 Glaucoma 360 Attendee Survey Hits All-Time High

Ophthalmologist (MD) and optometrist (OD) attendees of the 2024 Glaucoma 360 (G360) meeting demonstrated a record interest in participating in the Ninth Annual G360 Survey powered by Market Scope. ...

2/22/2024
GlaucomaMeetingNewsletterSurgical
Top Innovators Delve into Latest Concepts at G360’s New Horizons Forum
Top Innovators Delve into Latest Concepts at G360’s New Horizons Forum

Two of ophthalmology’s leading innovators headlined the New Horizons Forum at the Glaucoma 360 meeting. Sean Ianchulev, MD—arguably the most prolific ophthalmic product inventor in the US—led off t...

2/22/2024
GlaucomaMeetingNewsletterRegulation
Reimbursement Issues for Glaucoma Surgery Remain Threat, G360 Speakers Say
Reimbursement Issues for Glaucoma Surgery Remain Threat, G360 Speakers Say

Attendees of the G360 New Horizons Forum received a detailed breakdown of the battle that the ophthalmic industry collectively waged throughout 2023 to stop proposed limits to Medicare coverage for...

2/22/2024
GlaucomaNewsletter
Glaucoma Specialist H. Dunbar Hoskins Jr., MD, Dies at 84
Glaucoma Specialist H. Dunbar Hoskins Jr., MD, Dies at 84

Glaucoma specialist H. Dunbar Hoskins Jr., MD, a longtime executive of the American Academy of Ophthalmology who helped shape the society, died Jan. 27, the AAO reported. Hoskins was 84. He served ...

2/22/2024
CornealEmergingGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, February 2024
Emerging Companies Pursuing Ophthalmic Indications, February 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

2/22/2024
CataractClinical TrialCornealDealsDiagnosticDry EyeGene TherapyGlaucomaIOLIndustryNewsletterPresbyopiaRegulationRetinaSurgical
February 2024 Ophthalmic News Briefs
February 2024 Ophthalmic News Briefs

Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...

2/9/2024
BreakingDealsGlaucomaPharma
Nicox Licenses NCX 470 (Bimatoprost) Drop for Glaucoma to Kowa for Japan for $3.2 Million Up Front
Nicox Licenses NCX 470 (Bimatoprost) Drop for Glaucoma to Kowa for Japan for $3.2 Million Up Front

France’s Nicox announced Feb. 8 that it had signed a deal granting Japanese drug company Kowa exclusive Japanese rights to develop and commercialize Nicox’ NCX 470 (0.1% bimatoprost) eye drop for g...

2/2/2024
BreakingGlaucoma
Glaucoma Specialist H. Dunbar Hoskins Jr., MD, Dies at 84
Glaucoma Specialist H. Dunbar Hoskins Jr., MD, Dies at 84

Glaucoma specialist H. Dunbar Hoskins Jr., MD, a longtime executive of the American Academy of Ophthalmology who helped shape the society, died Jan. 27, the AAO reported. Hoskins was 84. He served ...

1/26/2024
BreakingGlaucomaIOLPharmaRevenueSurgical
2023 Ophthalmic Revenue Roundup for J&J Vision and Nicox
2023 Ophthalmic Revenue Roundup for J&J Vision and Nicox

Johnson & Johnson reported Jan. 23 that its full year 2023 global surgical vision revenue was $1.37 billion, a 4.9 percent increase (+5.8 percent cc) over $1.31 billion in 2022. Revenue was down 1....

1/23/2024
GlaucomaLaserNewsletter
Belkin Vision’s Eagle Laser for Glaucoma Receives FDA 510(k) Clearance
Belkin Vision’s Eagle Laser for Glaucoma Receives FDA 510(k) Clearance

Israeli company Belkin Vision reported Dec. 12 that its Eagle laser for glaucoma had gained US FDA 510(k) clearance. The Eagle is intended for use in performing a new automated, noncontact, one-sec...

1/23/2024
GlaucomaNewsletterRegulationSurgical
US FDA Approves iDose TR (Travoprost Implant) from Glaukos for Glaucoma
US FDA Approves iDose TR (Travoprost Implant) from Glaukos for Glaucoma

Glaukos reported Dec. 14 that the US FDA had approved its new drug application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, indicated for the reduction ...

1/23/2024
CataractClinical TrialDry EyeGene TherapyGlaucomaNewsletterPharmaRetina
Clinical Trial Updates for Ophthalmic Candidates, January 2024
Clinical Trial Updates for Ophthalmic Candidates, January 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

1/23/2024
GlaucomaNewsletterRegulationSurgical
2023 in Review: MAC Turmoil Shifts Landscape for Canal-Based Glaucoma Devices
2023 in Review: MAC Turmoil Shifts Landscape for Canal-Based Glaucoma Devices

Medicare administrative contractors (MACs) threw the near-term future of the glaucoma device market into turmoil in early 2023 when they challenged the medical necessity of canal-based surgical pro...

1/23/2024
CataractCornealDealsDry EyeGene TherapyGlaucomaIndustryLaserNewsletterOCTRegulationRetina
January 2024 Ophthalmic News Briefs
January 2024 Ophthalmic News Briefs

Maker of Sophi Phaco Machines UK-based Rayner announced Jan. 17 that it had acquired Switzerland’s This AG, the maker of Sophi phacoemulsification machines. No financial details were disclosed. Sop...

1/19/2024
BreakingGlaucomaLaserRetina
New Iridex 532 and Iridex 577 Lasers Launched in US Market
New Iridex 532 and Iridex 577 Lasers Launched in US Market

Iridex announced Jan. 11 the US launch of its next-generation Iridex 532 green and Iridex 577 yellow lasers for retina and glaucoma. Iridex, of Mountain View, California, said both lasers include c...

1/12/2024
BreakingGlaucomaRegulationSurgical
US MACs Retire Coverage Policies That Would Have Limited Some MIGS Procedures
US MACs Retire Coverage Policies That Would Have Limited Some MIGS Procedures

Five Medicare administrative contractors (MACs) have withdrawn and retired final policies that would have stopped Medicare coverage of common minimally invasive glaucoma surgeries in their US juris...

12/29/2023
BreakingCataractDealsGlaucomaMergersPharma
Ophthalmic Drugmaker Visiox to Merge with SPAC to Gain Nasdaq Listing
Ophthalmic Drugmaker Visiox to Merge with SPAC to Gain Nasdaq Listing

Privately held Visiox Pharmaceuticals reported Dec. 27 that it will gain a listing on the Nasdaq through a merger with PowerUp Acquisition Corp., a special purpose acquisition company (SPAC) based ...

12/29/2023
BreakingDiagnosticGlaucomaRegulationRetina
iHealthScreen Gains UK Approval for iPredict AI Screener for DR, AMD, and Glaucoma
iHealthScreen Gains UK Approval for iPredict AI Screener for DR, AMD, and Glaucoma

New York-based iHealthScreen announced Dec. 5 that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had approved its iPredict automated AI screening system for early diagnosis of d...

12/15/2023
BreakingGlaucomaLaserRegulation
Belkin Vision’s Eagle Laser Receives FDA 510(k) Clearance
Belkin Vision’s Eagle Laser Receives FDA 510(k) Clearance

Israeli company Belkin Vision reported Dec. 12 that its Eagle laser for glaucoma had gained US FDA 510(k) clearance. The Eagle is intended for use in performing a new automated, noncontact, one-sec...

12/15/2023
BreakingGlaucomaRegulationSurgical
US FDA Approves iDose TR (Travoprost Implant) from Glaukos for Glaucoma
US FDA Approves iDose TR (Travoprost Implant) from Glaukos for Glaucoma

Glaukos reported Dec. 14 that the US FDA had approved its new drug application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, indicated for the reduction ...

12/14/2023
GlaucomaIOLNewsletterRefractiveRetina
Ophthalmologists Report 6.4 Percent Decline in Q3-2023 Procedure Volume
Ophthalmologists Report 6.4 Percent Decline in Q3-2023 Procedure Volume

US ophthalmologists reported that ophthalmic procedures decreased 6.4 percent in Q3-2023 compared with the same quarter in 2022, according to Market Scope’s latest survey. Year-over-year performanc...

12/14/2023
AAOGlaucomaMIGSMeetingNewsletter
AAO Glaucoma Day Session Evaluates Latest Devices Advancing or Sold Outside the US
AAO Glaucoma Day Session Evaluates Latest Devices Advancing or Sold Outside the US

US glaucoma specialists have over 20 surgical options to treat their patients, but even more devices are available or in the pipeline outside the US, and their developers could seek FDA approval. M...

12/14/2023
CataractDeviceEarningsGlaucomaNewsletterPharmaRetinaRevenue
Ophthalmic Company Revenue Increases 3.4 Percent in Third Quarter of 2023
Ophthalmic Company Revenue Increases 3.4 Percent in Third Quarter of 2023

Ophthalmic manufacturer revenue in Q3-2023 totaled $11.1 billion. Revenue increased 3.4 percent from the same quarter in 2022 and decreased 2.7 percent from Q2-2023. The total includes Market Scope...

12/14/2023
BiosimilarsEmergingGene TherapyGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, December 2023
Emerging Companies Pursuing Ophthalmic Indications, December 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

12/14/2023
Clinical TrialDry EyeGlaucomaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, December 2023
Clinical Trial Updates for Ophthalmic Candidates, December 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

12/14/2023
Dry EyeGlaucomaNewsletterPharmaPresbyopiaRegulationRetina
FDA Approves 11 Ophthalmic Drug Products in 2023, Rejects Three More
FDA Approves 11 Ophthalmic Drug Products in 2023, Rejects Three More

2023 was a busy year for the US FDA in ophthalmology. Among the 11 drug products approved were the first two therapies in the US to treat geographic atrophy; two new drops for dry eye; and a second...

12/14/2023
CataractClinical TrialDealsDiagnosticGene TherapyGlaucomaIndustryNewsletterRegulationRetinaTelehealth
December 2023 Ophthalmic News Briefs
December 2023 Ophthalmic News Briefs

Enzene Biosciences, based in Pune, India, announced in November that it had launched a ranibizumab biosimilar for the treatment of wet age-related macular degeneration (AMD). The product references...

12/8/2023
BreakingGlaucomaSurgical
France’s Ciliatech Unveils New Design of CID Glaucoma Surgical Device
France’s Ciliatech Unveils New Design of CID Glaucoma Surgical Device

France’s Ciliatech revealed on Dec. 5 a new design of its CID (Cilioscleral Interpositioning Device), following the filing of additional patents. Ciliatech says its approach with the CID avoids the...

12/8/2023
BreakingCataractGlaucomaIOLIndustry
SpyGlass Pharma Appoints Margot Goodkin, MD, PhD, as Chief Medical Officer
SpyGlass Pharma Appoints Margot Goodkin, MD, PhD, as Chief Medical Officer

SpyGlass Pharma announced Dec. 5 that it had appointed Margot Goodkin, MD, PhD, as chief medical officer. Goodkin is a glaucoma fellowship-trained ophthalmologist and biopharmaceutical industry vet...

11/22/2023
BreakingEuropeGlaucomaPharmaRegulation
Santen Receives EU Approval for Catiolanze (Preservative-Free Latanoprost) in Glaucoma
Santen Receives EU Approval for Catiolanze (Preservative-Free Latanoprost) in Glaucoma

Japanese drugmaker Santen Pharmaceutical announced Nov. 17 that the European Commission had approved its marketing authorization application for preservative-free Catiolanze (cationic emulsion of l...

11/21/2023
CornealDiagnosticDry EyeFundingGlaucomaNewsletterRetina
EyeBio Leads Latest Ophthalmic Fundraising with $65 Million in Series A
EyeBio Leads Latest Ophthalmic Fundraising with $65 Million in Series A

EyeBio led recent ophthalmic fundraising efforts with $65 million in Series A funding to continue development of its candidate for retinal disease. Financing announced in the past four weeks totale...

11/21/2023
DiagnosticGlaucomaLaserNewsletterRegulationRetina
Select US FDA Approvals and Clearances in October 2023
Select US FDA Approvals and Clearances in October 2023

The US FDA granted five clearances through the ophthalmic device division using the 510(k) pathway in October 2023, according to the agency’s database. Heidelberg gained market clearance for its An...

11/21/2023
DealsGlaucomaNewsletter
Stuart Therapeutics Licenses its Glaucoma Neuroprotection Candidate to Glaukos
Stuart Therapeutics Licenses its Glaucoma Neuroprotection Candidate to Glaukos

Stuart Therapeutics announced Oct. 18 that it had granted Glaukos exclusive worldwide rights to develop and commercialize Stuart’s ST-113 drug candidate for neuroprotection in glaucoma. ST-113 is a...

11/21/2023
Clinical TrialCornealGlaucomaNewsletterRegulationRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, November 2023
Clinical Trial Updates for Ophthalmic Candidates, November 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

11/21/2023
AAODiagnosticDigitalDry EyeGlaucomaMeetingNewsletterRefractiveRegulationRetinaSurgical
Buzzworthy Topics at the 2023 AAO Meeting
Buzzworthy Topics at the 2023 AAO Meeting

Dry Eye: New products kept generating buzz around dry eye. Bausch + Lomb leaned into the promotion of Miebo, the new, first-in-class drug therapy that directly targets tear evaporation. Diagnostic ...

11/21/2023
AAODigitalDry EyeEyeceleratorGlaucomaMeetingNewsletterRetina
Eyecelerator at AAO Showcases Innovators and Awards $45 Thousand in Prize Money
Eyecelerator at AAO Showcases Innovators and Awards $45 Thousand in Prize Money

Eyecelerator awarded a total of $45 thousand in prize money to winning pitch challengers at its fall meeting, after emerging companies got a chance to work with accomplished industry veterans to re...

11/21/2023
AAOCataractDiagnosticDigitalGlaucomaMeetingNewsletterSurgical
Diagnostic Leaders Showcase Devices, Collaborations at AAO Meeting
Diagnostic Leaders Showcase Devices, Collaborations at AAO Meeting

Notable diagnostic innovations showcased at the 2023 meeting of the American Academy of Ophthalmology were Topcon’s Tempo perimeter and Heidelberg Engineering’s Anterion anterior OCT platform. Also...

11/21/2023
GlaucomaNewsletterRegulationSurgical
Five MACs Finalize Plans to Curb Coverage of Non-stent Glaucoma Procedures
Five MACs Finalize Plans to Curb Coverage of Non-stent  Glaucoma Procedures

Five of the seven Medicare administrative contractors (MACs) in the US have issued their final reimbursement plans for minimally invasive glaucoma surgery (MIGS) procedures, confirming that they wo...

11/21/2023
CornealDiagnosticEmergingGene TherapyGlaucomaNewsletterRetinaSurgical
Emerging Companies Pursuing Ophthalmic Indications, November 2023
Emerging Companies Pursuing Ophthalmic Indications, November 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

11/21/2023
ChinaDealsDiagnosticDry EyeGene TherapyGenericsGlaucomaIndustryNewsletterPresbyopiaRegulationRetinaSurgical
November 2023 Ophthalmic News Briefs
November 2023 Ophthalmic News Briefs

Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis, with offices in the US and Israe...

11/10/2023
BreakingDry EyeGlaucomaIOLLaserRevenue
Q3-2023 Ophthalmic Revenue Roundup for Hoya, Lumibird, Sight Sciences, and Ocular Therapeutix
Q3-2023 Ophthalmic Revenue Roundup for Hoya, Lumibird, Sight Sciences, and Ocular Therapeutix

Japan-based Hoya Corporation reported Oct. 31 that its medical segment (IOLs, endoscopes, and artificial bone) generated revenue for the third quarter of 2023—its fiscal year Q2-2023—of ¥33.5 billi...

11/3/2023
BreakingDry EyeGlaucomaPharmaRefractiveRetinaRevenueSurgical
Q3-2023 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, AbbVie, and Five Others
Q3-2023 Ophthalmic Revenue Roundup for Regeneron, Bausch +  Lomb, AbbVie, and Five Others

Regeneron of Tarrytown, New York, reported Nov. 2 that its Q3-2023 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was $1.49 billion, with Eylea HD accou...

10/27/2023
BiologicsBreakingDry EyeGlaucomaPharmaRetinaRevenueSurgical
Q3-2023 Ophthalmic Revenue Roundup for Roche, Novartis, J&J Vision, and Nicox
Q3-2023 Ophthalmic Revenue Roundup for Roche, Novartis, J&J Vision, and Nicox

Swiss company Roche reported Oct. 19 that Q3-2023 Vabysmo sales were CHF 656 million ($732 million, converted Oct. 19), a 309 percent increase over CHF 173 million in Q3-2022. Vabysmo was approved ...

10/27/2023
BreakingDealsGlaucomaPharma
Stuart Therapeutics Licenses its Glaucoma Neuroprotection Candidate to Glaukos
Stuart Therapeutics Licenses its Glaucoma Neuroprotection Candidate to Glaukos

Stuart Therapeutics announced Oct. 18 that it had granted Glaukos exclusive worldwide rights to develop and commercialize Stuart’s ST-113 drug candidate for neuroprotection in glaucoma. ST-113 is a...

10/24/2023
CataractDry EyeESCRSGlaucomaIOLMeetingNewsletterRegulationSurgical
Buzzworthy Topics at the 2023 ESCRS Congress
Buzzworthy Topics at the 2023 ESCRS Congress

Minimally Invasive Glaucoma Surgery (MIGS): The ESCRS highlighted the growing importance of MIGS this year by holding the meeting’s first MIGS master class. Several speakers in other sessions extol...

10/24/2023
GlaucomaLaserNewsletterRetina
Ophthalmic Laser Companies Look to Improve on Convenience, Experience
Ophthalmic Laser Companies Look to Improve on Convenience, Experience

The therapeutic ophthalmic laser market will experience modest growth in the next five years, as laser manufacturers focus on improving convenience and experience for ophthalmologists and patients....

10/24/2023
ChinaDiagnosticDry EyeEmergingGene TherapyGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, October 2023
Emerging Companies Pursuing Ophthalmic Indications, October 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

10/20/2023
BreakingDry EyeGlaucomaIndustryRegulation
Sight Sciences to Cut 25 Employees as it Awaits MACs’ Coverage Decision
Sight Sciences to Cut 25 Employees as it Awaits MACs’ Coverage Decision

Sight Sciences, of Menlo Park, California, has informed its employees that it will cut its workforce of 250 by 25 employees as it awaits a final decision by five of the seven Medicare Administrativ...

10/20/2023
BreakingGlaucomaPharma
Padagis Launches Generic Brinzolamide Drop for Glaucoma
Padagis Launches Generic Brinzolamide Drop for Glaucoma

Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis with offices in the US and Israel...

9/29/2023
BreakingGlaucomaPharma
Théa Launches Preservative-Free Iyuzeh (Latanoprost) for Glaucoma in the US
Théa Launches Preservative-Free Iyuzeh (Latanoprost) for Glaucoma in the US

Théa Pharma, the US subsidiary of France’s Laboratoires Théa, announced the launch Sept. 26 of once-daily Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh is the first prese...

9/22/2023
BreakingCataractDry EyeGlaucomaIndustryPharma
Mati Completes Facility to Manufacture Evolute Punctal Plug Portfolio
Mati Completes Facility to Manufacture Evolute Punctal Plug Portfolio

Mati Therapeutics, of Austin, Texas, reported Sept. 12 that it had completed a 10 thousand square foot facility in Bryan, Texas, to manufacture the company’s Evolute sustained drug delivery platfor...

9/21/2023
GlaucomaIOLNewsletterRefractiveRetina
Ophthalmologists Report 4.9 Percent Decrease in Q2-2023 Procedure Volume
Ophthalmologists Report 4.9 Percent Decrease in Q2-2023 Procedure Volume

US ophthalmologists reported that ophthalmic procedures decreased 4.9 percent in Q2-2023 compared with the same quarter in 2022, according to Market Scope’s latest survey. Year-over-year performanc...

9/21/2023
GlaucomaLaserNewsletter
Laser Company Iridex to Undergo Strategic Review
Laser Company Iridex to Undergo Strategic Review

Iridex announced Aug. 29 that it would undergo a review of strategic alternatives, with Piper Sandler acting as financial advisor. The Mountain View, California, ophthalmic laser company said there...

9/21/2023
GlaucomaIOLNewsletterRetina
Select US FDA Approvals and Clearances in August 2023
Select US FDA Approvals and Clearances in August 2023

The US FDA granted four clearances through the ophthalmic device division using the 510(k) pathway in August 2023, according to the agency’s database. RxSight received clearance for a new IOL injec...

9/21/2023
CataractDry EyeGlaucomaNewsletterRegulation
FDA Warns Eight Companies Over Marketing Unapproved or Unsafe Eye Drops in the US
FDA Warns Eight Companies Over Marketing Unapproved or Unsafe Eye Drops in the US

The US FDA reported Sept. 12 that it had issued warning letters to eight companies for manufacturing or marketing unapproved eye drug products, expanding the list of companies that the FDA has targ...

9/21/2023
DiagnosticGlaucomaNewsletterRefractiveRetinaSurgical
Ophthalmic Diagnostic Equipment Market To Grow 3.8 Percent Through 2028, Driven by OCT Systems
Ophthalmic Diagnostic Equipment Market  To Grow 3.8 Percent Through 2028, Driven  by OCT Systems

Market Scope estimates that the ophthalmic diagnostic equipment market will generate $3.7 billion in total revenue in 2023, and the market will grow to $4.4 billion by 2028, for a compound annual g...

9/21/2023
Clinical TrialCornealDry EyeGene TherapyGlaucomaNewsletterRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, September 2023
Clinical Trial Updates for Ophthalmic Candidates, September 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

9/21/2023
GenericsGlaucomaNewsletterPharma
Apotex Launches Brimonidine Tartrate 0.1% Ophthalmic Solution in US
Apotex Launches Brimonidine Tartrate 0.1% Ophthalmic Solution in US

Apotex announced Sept. 5 that it had launched its generic brimonidine tartrate 0.1% ophthalmic solution in the US. Brimonidine is an alpha-adrenergic receptor agonist indicated for the reduction of...

9/21/2023
GlaucomaNewsletterSurgical
Weekly Surgeon Poll, September 2023
Weekly Surgeon Poll, September 2023

9/15/2023
BreakingCataractDry EyeGlaucomaRegulation
FDA Warns Eight Companies Over Marketing Unapproved Eye Drops
FDA Warns Eight Companies Over Marketing Unapproved Eye Drops

The US FDA reported Sept. 12 that it had issued warning letters to eight companies for manufacturing or marketing unapproved eye drug products, expanding the list of companies that the FDA has targ...

9/15/2023
BreakingGlaucomaIndustryRetina
Neurotech Adds Alex Gorsky to its Board as Lead Director
Neurotech Adds Alex Gorsky to its Board as Lead Director

Neurotech Pharmaceuticals reported Sept. 13 that Alex Gorsky had been elected to its board as lead director. Gorsky, former chairman and chief executive officer of Johnson & Johnson, stepped down f...

9/8/2023
BreakingGenericsGlaucomaPharma
Apotex Launches Brimonidine Tartrate 0.1% Ophthalmic Solution in US
Apotex Launches Brimonidine Tartrate 0.1% Ophthalmic Solution in US

Apotex announced Sept. 5 that it had launched its generic brimonidine tartrate 0.1% ophthalmic solution in the US. Brimonidine is an alpha-adrenergic receptor agonist indicated for the reduction of...

9/1/2023
BreakingDealsGlaucomaIndustryLaserRetina
Iridex to Undergo Strategic Review
Iridex to Undergo Strategic Review

Iridex announced Aug. 29 that it would undergo a review of strategic alternatives, with Piper Sandler acting as financial advisor for the process. The Mountain View, California, ophthalmic laser co...

8/25/2023
BreakingClinical TrialGlaucomaRetina
Tarsier’s Dazdotuftide Misses Phase III Primary Endpoint, Shows Promise for Uveitic Glaucoma
Tarsier’s Dazdotuftide Misses Phase III Primary Endpoint, Shows Promise for Uveitic Glaucoma

Israel’s Tarsier Pharma reported Aug. 23 that its TRS01 (dazdotuftide) eye drops failed to meet the primary inflammation endpoint in a Phase III trial in patients with active noninfectious anterior...

8/22/2023
CataractClinical TrialGlaucomaIOLNewsletterPharmaRetina
Clinical Trial Updates for Ophthalmic Candidates, August 2023
Clinical Trial Updates for Ophthalmic Candidates, August 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

8/22/2023
CataractGlaucomaNewsletterRegulationSurgical
CMS Proposes Cut in 2024 Physician Payments, Increase in Facility Fees
CMS Proposes Cut in 2024 Physician Payments, Increase in Facility Fees

The Centers for Medicare and Medicaid Services (CMS) is proposing to cut the conversion factor for the Physician Fee Schedule (PFS)—one of four factors used in calculating Medicare payments to doct...

8/22/2023
Dry EyeGlaucomaNewsletterRefractiveRegulationRetina
US FDA Target Action Dates for Ophthalmic Drug Candidates, August to December 2023
US FDA Target Action Dates for Ophthalmic Drug Candidates, August to December 2023

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic prescription and biologic drug candidates and those classified as drug/device combin...

8/22/2023
AICataractDealsGlaucomaIOLIndustryNewsletterPharmaRegulationRetinaSingle-Use
August 2023 Ophthalmic News Briefs
August 2023 Ophthalmic News Briefs

New York’s Icahn School of Medicine at Mount Sinai announced July 5 that it had launched the Center for Ophthalmic Artificial Intelligence and Human Health. The center will incorporate AI into educ...

8/18/2023
BreakingCataractGlaucomaLaserPharmaRevenueSurgical
Q2-2023 Ophthalmic Revenue Roundup for Alcon, Immunocore, Harrow, and Two Others
Q2-2023 Ophthalmic Revenue Roundup for Alcon, Immunocore, Harrow, and Two Others

Alcon reported Aug. 15 that its Q2-2023 net sales totaled $2.4 billion, a 9 percent increase (+12 percent cc) over $2.2 billion in Q2-2022. Surgical net sales for implantables, consumables, and equ...

8/18/2023
BreakingCataractGlaucomaRegulationSurgical
CMS Proposes Cut in 2024 Physician Payments, Increase in Facility Fees
CMS Proposes Cut in 2024 Physician Payments, Increase in Facility Fees

The Centers for Medicare and Medicaid Services (CMS) is proposing to cut the conversion factor for the Physician Fee Schedule (PFS)—one of four factors used in calculating Medicare payments to doct...

8/10/2023
AllergyBreakingCataractGlaucomaIOLRevenueSurgical
Q2-2023 Ophthalmic Revenue Roundup for RxSight, LENSAR, Hoya, and Two Others
Q2-2023 Ophthalmic Revenue Roundup for RxSight, LENSAR, Hoya, and Two Others

Japan-based Hoya Corporation announced July 31 that its medical care segment (IOLs, endoscopes, artificial bone) had revenue for the quarter ending June 30, 2023—the first quarter of its fiscal yea...

8/10/2023
AIBreakingDiagnosticGlaucomaRetina
Icahn School of Medicine at Mount Sinai Launches Ophthalmic-Focused AI Center
Icahn School of Medicine at Mount Sinai Launches Ophthalmic-Focused AI Center

New York’s Icahn School of Medicine at Mount Sinai announced July 5 that it had launched the Center for Ophthalmic Artificial Intelligence and Human Health. The center will incorporate AI into educ...

8/10/2023
BreakingFundingGlaucomaPharmaStudy
NIH $2.5 Million Grant Funds Glaucoma Treatment Research at Missouri S&T
NIH $2.5 Million Grant Funds Glaucoma Treatment Research at Missouri S&T

The Missouri University of Science and Technology announced July 31 that one of its professors researching glaucoma treatments was awarded a grant from the National Institutes for Health that will ...

8/4/2023
BreakingGlaucomaRefractiveRetinaRevenueSurgical
Q2-2023 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, STAAR, and Two Others
Q2-2023 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, STAAR, and Two Others

Regeneron, of Tarrytown, New York, reported Aug. 3 that its Q2-2023 US revenue for Eylea was $1.5 billion, a 7 decrease from $1.62 billion in Q2-2022. The company attributed the decline to a lower ...

8/4/2023
BreakingGlaucomaPharmaRegulation
Amneal Submits Abbreviated NDA to US FDA for Generic Bimatoprost
Amneal Submits Abbreviated NDA to US FDA for Generic Bimatoprost

Amneal Pharmaceuticals announced July 26 that it had submitted an abbreviated new drug application (NDA) to the US FDA for bimatoprost ophthalmic solution 0.01%, a generic version of Lumigan, to tr...

7/28/2023
BreakingDry EyeGlaucomaIOLLaserRetinaRevenue
Q2-2023 Ophthalmic Revenue Roundup for Roche, Novartis, J&J Vision, and Two Others
Q2-2023 Ophthalmic Revenue Roundup for Roche, Novartis, J&J Vision, and Two Others

Swiss company Roche reported July 27 that Vabysmo sales for Q2-2023 were CHF 525 million ($606 million, converted July 27, 2023), a nearly 500 percent increase over CHF 88 million in Q2-2022. Roche...

7/25/2023
GlaucomaNewsletterRegulationSurgical
MACs Consider Ending Reimbursement for Some MIGS Procedures
MACs Consider Ending Reimbursement for Some MIGS Procedures

The near-term future of the US glaucoma device market is in the hands of Medicare administrative contractors (MACs) after increased use of minimally invasive glaucoma surgery (MIGS) procedures led ...

7/25/2023
GlaucomaMeetingNewsletter
Doctors at World Glaucoma Congress Embrace Lasers, Debate the Future of Patient Care
Doctors at World Glaucoma Congress Embrace Lasers, Debate the Future of Patient Care

Provocative ideas, controversies, and calls to action were all part of the 10th World Glaucoma Congress in Rome. Thefour-day meeting (June 28-July 1) was the largest World Glaucoma Congress ever, w...

7/25/2023
Dry EyeGlaucomaNewsletterPresbyopiaRegulationRetina
US FDA Target Action Dates for Ophthalmic Drug Candidates
US FDA Target Action Dates for Ophthalmic Drug Candidates

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic prescription and biologic drug candidates and those classified as drug/device combin...

7/25/2023
GlaucomaNewsletterSurgical
Evolving Glaucoma Treatment Approach Driving Growth in New Devices
Evolving Glaucoma Treatment Approach Driving Growth in New Devices

The quest for safer and more effective glaucoma surgery treatments for all stages of glaucoma has expanded significantly over the past several years, and Market Scope looks for continued investment...

7/25/2023
DealsDry EyeGlaucomaNewsletter
Santen Hands Over Rights for Eight Ophthalmic Pharma Products to Harrow, Visiox
Santen Hands Over Rights for Eight Ophthalmic Pharma Products to Harrow, Visiox

Japanese drugmaker Santen announced July 18 that Harrow had acquired US or Canadian commercial rights to seven of Santen’s branded eye drops, while Visiox Pharma had licensed US rights to Omlonti f...

7/25/2023
AllergyClinical TrialDry EyeGlaucomaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, July 2023
Clinical Trial Updates for Ophthalmic Candidates, July 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

7/25/2023
CornealFundingGlaucomaNewsletterRetina
NeuroGene Leads Latest Ophthalmic Fundraising with $95 Million Private Placement
NeuroGene Leads Latest Ophthalmic Fundraising with $95 Million Private Placement

Neurogene led recent ophthalmic fundraising efforts with a $95 million private placement, as it advances its pipeline, including a gene therapy candidate for Batten disease. Funding announced in th...

7/25/2023
GlaucomaMeetingNewsletterPharmaSurgical
Buzzworthy Topics at 2023 World Glaucoma Congress
Buzzworthy Topics at 2023 World Glaucoma Congress

Lasers: Impressive six-year results for SLT and new lasers fed growing interest in laser therapy for OHT and open-angle glaucoma. Personalized medicine and interventional glaucoma: Whether called “...

7/25/2023
EuropeGlaucomaMeetingNewsletterSurgical
European Glaucoma Society Expected to Issue New MIGS Guidelines
European Glaucoma Society Expected to Issue New MIGS Guidelines

Fotis Topouzis, MD, PhD (Greece), gave the World Glaucoma Congress a preview of the European Glaucoma Society’s new guidelines for minimally invasive glaucoma surgery (MIGS). The term “MIGS” in Eur...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more